Stereotaxis (STXS) AI Stock Analysis

• Market Cap: $204.38M
• Dividend Yield: N/A
• Average Volume (3M): 583.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 19.61%
• EPS Growth: -3.42%
• Country: US
• Employees: 139
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 93,324,760
• 10 Day Avg. Volume: 380,338
• 30 Day Avg. Volume: 583,610
• PEG Ratio: -0.73
• Price to Book (P/B): 16.99
• Price to Sales (P/S): 7.22
• P/FCF Ratio: -22.77
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 6.63
• Enterprise Value/Gross Profit: 12.50
• Enterprise Value/Ebitda: -8.99
• 1Y Price Target: $4.20
• Price Target Upside: 91.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: $2.50 ▲(14.16% Upside)

The score is driven primarily by weak financial performance (ongoing large losses and negative free cash flow despite strong gross margins), partially offset by a constructive earnings-call outlook highlighted by GenesisX FDA approval and expectations for accelerating revenue and recurring revenue. Technicals are mixed and valuation remains challenged due to unprofitable earnings and no dividend.

Positive Factors

MAGiC FDA approval

U.S. FDA approval removes a key regulatory barrier and enables full commercial rollout in the largest addressable market. This structurally increases opportunity for disposable catheter sales, supports recurring revenue growth, and accelerates broader adoption of Stereotaxis’ robotic platforms over time.

GenesisX FDA approval

GenesisX approval creates a durable product upgrade cycle and expands the system opportunity, which management expects to outpace prior Genesis orders. Structural system approvals drive long-term revenues from system sales, consumables, and service contracts, strengthening commercial runway.

Growing recurring revenue

Rising recurring revenue demonstrates increasing adoption of disposable catheters and mapping tools, creating more predictable, higher-margin cash flows. Durable recurring streams reduce reliance on one-time system sales and support sustainable top-line growth as installed base expands.

Negative Factors

Persistent large net losses

Sustained substantial net losses indicate operations are not yet profitable and will pressure retained earnings and returns. Over the medium term this limits reinvestment capacity, increases dependence on external financing, and makes achieving durable profitability a critical structural challenge.

Negative free cash flow / cash burn

Continued negative free cash flow signals ongoing cash burn from operations and commercialization. Structurally this reduces financial flexibility, may require additional capital or dilution, and constrains the company’s ability to fund growth initiatives or scale sales and R&D without external financing.

Low equity backing / limited balance sheet cushion

A low equity ratio and near‑unit leverage provide limited asset backing and less cushion against shocks. Structurally this raises refinancing and dilution risk, constrains strategic investments, and reduces flexibility to absorb operational setbacks while pursuing commercialization and approval milestones.

Stereotaxis Business Overview & Revenue Model

Company Description

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

How the Company Makes Money

Stereotaxis generates revenue through the sale of its robotic systems, which include the Niobe™ ES and Niobe™ Magnetic Navigation Systems, as well as through the sale of disposable catheters used in procedures. The company's revenue model includes upfront system sales, recurring revenues from the sale of disposable catheters, and service contracts for system maintenance and support. Significant partnerships with hospitals and medical institutions enhance its market reach and provide consistent revenue streams. In addition, Stereotaxis may benefit from ongoing research collaborations and clinical studies that drive demand for its technologies.

Stereotaxis Financial Statement Overview

Summary

Solid gross margin (~54% in 2024) and marginal revenue growth are outweighed by persistent, very large net losses (net margin about -94% in 2024) and negative EBIT/EBITDA. Leverage is roughly balanced (debt-to-equity ~0.99) but equity backing is low (~13% equity ratio), and free cash flow remains negative, indicating ongoing cash burn and the need for cost and cash-flow improvement.

Income Statement

Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.

Balance Sheet

The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.

Cash Flow

Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.07M	26.92M	26.77M	28.15M	35.02M	26.63M
Gross Profit	15.96M	14.59M	14.86M	18.47M	23.23M	18.97M
EBITDA	-22.20M	-23.77M	-21.24M	-18.35M	-12.78M	-6.59M
Net Income	-23.63M	-24.05M	-20.71M	-18.29M	-10.72M	-6.65M
Balance Sheet
Total Assets	45.59M	46.72M	41.91M	53.41M	60.98M	55.46M
Cash, Cash Equivalents and Short-Term Investments	10.51M	12.22M	19.82M	28.43M	38.74M	43.94M
Total Debt	5.58M	6.01M	5.49M	5.86M	6.11M	4.45M
Total Liabilities	34.05M	35.29M	19.99M	21.48M	21.56M	15.23M
Stockholders Equity	11.53M	11.43M	21.92M	31.93M	39.42M	40.23M
Cash Flow
Free Cash Flow	-4.27M	-8.53M	-9.51M	-10.79M	-4.34M	-3.58M
Operating Cash Flow	-4.25M	-8.50M	-9.14M	-8.41M	-2.95M	-3.51M
Investing Cash Flow	-25.00K	74.00K	19.77M	-22.09M	-1.40M	-70.90K
Financing Cash Flow	225.00K	297.00K	81.00K	220.00K	547.00K	17.34M

Stereotaxis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 2.19 is below the 20-day moving average (MA) of 2.57, below the 50-day MA of 2.44, and below the 200-day MA of 2.48, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 32.97 is Neutral, neither overbought nor oversold. The STOCH value of 5.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.

Stereotaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	77 Outperform	$4.81B	41.50	8.30%	―	11.49%	-2.89%
LMAT	75 Outperform	$1.93B	36.56	15.02%	0.95%	13.07%	27.98%
ATRC	73 Outperform	$1.84B	-60.74	-6.11%	―	15.80%	26.94%
STXS	62 Neutral	$204.38M	-7.79	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	46 Neutral	$942.61M	-9.68	-24.65%	―	-32.42%	-540.37%
MLSS	42 Neutral	$22.09M	-3.40	-136.47%	―	0.59%	-39.76%